How can DNA methylation clocks, histone modification patterns, and epigenetic age acceleration serve as biomarkers for Alzheimer disease, Parkinson disease, and related neurodegenerative conditions? Focus areas: 1. Diagnostic biomarker utility: Can epigenetic clocks distinguish AD from other dementias? What is the sensitivity/specificity? 2. Prognostic value: Does epigenetic age acceleration correlate with disease progression, cognitive decline rate, or conversion from MCI to AD? 3. Biomarker validation: What blood, CSF, or tissue samples are available for validation? Which clock algorithms (Horvath, Hannum, PhenoAge, GrimAge) perform best? 4. Mechanistic links: How do epigenetic changes relate to tau pathology, amyloid burden, alpha-synuclein, TDP-43, and other neurodegenerative hallmarks? 5. Confounding factors: How do comorbidities (vascular disease, diabetes), lifestyle, and cell type composition affect epigenetic biomarker readings? The existing gap on therapeutic approaches (gap-v2-bc5f270e) addressed epigenetic clock modulation as therapy. This gap focuses specifically on biomarker development and validation for diagnosis, prognosis, and disease monitoring.
Landscape Summary: Epigenetic clocks as biomarkers for Alzheimer disease and neurodegeneration is a 0.85 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: resolved.
Colonna, Sevlever, et al. (TREM2 biology)
Epigenetic clocks as biomarkers for Alzheimer disease and neurodegeneration — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: